MetaVia Inc Dossier - Source-backed chat

MetaVia Inc

MTVANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.92

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.54Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $10.1M

Enterprise Value −$2.5M

Shares Outstanding 6M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

MetaVia Inc. (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, specifically targeting obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company's investment thesis is anchored on its highly differentiated pipeline, led by DA-1726, a novel oxyntomodulin (OXM) analogue functioning as a GLP-1R/GCGR dual agonist, and vanoglipel (DA-1241), a GPR119 agonist. Early clinical data for DA-1726 demonstrates best-in-class potential, showing robust weight loss, glycemic control, and direct hepatic benefits with a favorable tolerability profile. While the company operates with a lean team and faces typical clinical-stage cash burn, its strategic partnership with Dong-A ST Co., Ltd. and the massive addressable markets for obesity and MASH provide a compelling risk-reward profile at its current low valuation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$19.33

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$8.0020%

DA-1726 Phase 1 Part 3 data reveals safety or tolerability issues at higher doses (64 mg), limiting its competitive differentiation. Vanoglipel development is delayed or discontinued due to capital constraints. The company is unable to secure non-dilutive financing or strategic partnerships, forcing highly dilutive equity raises that depress shareholder value.

Base CaseCentral scenario

$14.0050%

MetaVia successfully completes the Phase 1 Part 3 titration study of DA-1726 by late 2026, confirming optimized tolerability at higher doses (up to 64 mg) and robust exploratory weight loss. The company finalizes the Phase 2a Clinical Study Report for vanoglipel, showing consistent hepatoprotective and glucose-regulating effects. The board executes a reverse stock split to maintain Nasdaq compliance, stabilizing the share price and attracting institutional investors.

Bull CaseUpside scenario

$20.0030%

DA-1726 demonstrates superior weight loss and tolerability in Phase 1 Part 3 trials compared to existing GLP-1 therapies, positioning it as a best-in-class dual agonist. Vanoglipel successfully advances into Phase 2b trials for MASH with strong hepatoprotective data. The company secures a major pharmaceutical co-development partnership, triggering milestone payments and fully funding its late-stage clinical pipeline, leading to a significant upward re-rating of the stock.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated dual-agonist mechanism of DA-1726 (GLP-1R/GCGR) which reduces appetite while simultaneously increasing energy expenditure, potentially yielding superior weight loss compared to selective GLP-1 agonists.
Strong early clinical data showing robust weight loss (9.1% in 8 weeks at 48 mg non-titrated), waist circumference reduction, and direct hepatic benefits (23.7% reduction in liver stiffness).
Strategic backing and exclusive licensing from Dong-A ST Co., Ltd., a leading South Korean pharmaceutical company.
Robust global intellectual property portfolio supporting DA-1726 with 39 granted and pending patents providing protection into at least 2041.

Key Investment Risks

High cash burn rate typical of clinical-stage biotechnology companies, with a limited financial runway expected to fund operations into late 2026.
Regulatory and clinical development risks, including potential safety, tolerability, or efficacy hurdles in upcoming higher-dose trials.
Nasdaq listing compliance risk due to the low share price, requiring a reverse stock split to maintain the minimum bid price requirement.
Intense competition in the obesity and MASH therapeutic spaces from well-capitalized global pharmaceutical giants.

Thesis Invalidation Triggers

Failure of DA-1726 to meet safety, tolerability, or efficacy endpoints in the Phase 1 Part 3 titration study.
Inability to secure additional financing or strategic partnerships before the exhaustion of current cash reserves.
Severe clinical holds or regulatory rejections imposed by the FDA on lead assets DA-1726 or vanoglipel.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.